Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glenzocimab in Acute Ischemic Stroke
NCT05070260Phase 3Completed
- Sponsor
- Acticor Biotech
- Start
- Sep 2021
- Primary completion
- Apr 2024
- Modality
- Antibody Fragments
- Countries
- 2
01
Overview
A Phase 3 trial of glenzocimab in ischemic stroke, sponsored by Acticor Biotech. Started Sep 2021; status: completed.
02
Drugs
glenzocimab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05070260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070260.